Data support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under ...

PARIS, France and TARRYTOWN, NY, USA I March 8, 2025 I Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD . Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared ...